Event-Based Pharmacovigilance

Event-based pharmacovigilance systematically investigates individual adverse event reports identifying potential safety signals warranting regulatory attention. Case evaluation determines causal relationship between drug exposure and adverse outcome. Serious adverse event reports trigger expedited regulatory notification. Signal detection algorithms identify unexpected adverse event clustering warranting investigation.

Regulatory submissions to competent authorities occur within defined timelines following serious adverse events. Periodic Safety Update Reports summarise cumulative adverse event experience. Medical literature monitoring identifies published case reports of adverse events. Healthcare provider and patient reporting systems capture diverse adverse event sources. Regulatory actions including label modifications or market restrictions result from identified safety signals.